B‐lymphocyte contributions to human autoimmune disease

  title={B‐lymphocyte contributions to human autoimmune disease},
  author={Koichi Yanaba and J. D. Bouaziz and Takashi Matsushita and Cynthia M. Magro and E. William St.Clair and Thomas F. Tedder},
  journal={Immunological Reviews},
Summary: Autoimmunity results from abnormal B‐ and T‐cell recognition of self‐antigens, which leads to autoantibody production in many cases. Autoantibodies produced by B‐cell‐derived plasma cells provide diagnostic markers for autoimmunity but also contribute significantly to disease pathogenesis. As discussed in this review, the therapeutic benefit of depleting B cells in mice and humans has refocused attention on B cells and their role in autoimmunity beyond autoantibody production. B cells… 

Regulatory B cells in autoimmune diseases

This review focuses on the recent advances that lead to the understanding of the development and function of Breg cells and the implications of B cells in human autoimmune diseases.

B-lymphocyte depletion for the treatment of multiple sclerosis: now things really get interesting

Clinically, pan-mature B-cell depletion in humans using a CD20 monoclonal antibody (mAb; rituximab) is effective for treating various autoimmune disorders in some patients, such as rheumatoid arthritis, and recent Phase I and II trials using ritUXimab suggest clinical eff icacy in MS patients.

IL‐10–producing regulatory B cells in skin diseases

The frequency of IL‐10–producing B cells in the peripheral blood from patients with systemic sclerosis and systemic lupus erythematosus was decreased and the function of regulatory B cells was impaired in patients withSystemic sclerosis, and patients with cutaneous T‐cell lymphoma showed decreased number of IL-10– producing B cells.

B lymphocytes in systemic sclerosis: Abnormalities and therapeutic targets

Altered B‐cell function may result in tissue fibrosis, as well as autoimmunity, in SSc, and B cells are potential therapeutic target in S sc.

Regulatory B cells as inhibitors of immune responses and inflammation

A specific and functionally important subset of B cells can also negatively regulate immune responses in mouse autoimmunity and inflammation models, and this review focuses on the recent progress in this field and the exciting opportunities for understanding how this unique B‐cell subset influences diverse immune functions.

B cells participate in tolerance and autoimmunity through cytokine production

The role of B cells in autoimmunity is reviewed, mainly through their ability to produce cytokines, as the B cell cytokine network produced by B cell subsets were shown to influence T cell numbers, as well as the polarization of T cell subset (Tregs/Th1/Th2).

B10 cell regulation of health and disease

B10 cells function in an antigen‐specific manner that requires cognate interactions with T cells in vivo to regulate immune responses and have been demonstrated to be potent regulators of allergic and autoimmune disease, cancer, infection, and transplant rejection.

B lymphocytes: Shedding new light on the pathogenesis of systemic sclerosis

  • M. Hasegawa
  • Biology, Medicine
    The Journal of dermatology
  • 2010
As B cells have a variety of functions, further investigation into the pathogenic roles of B cells, as well as trials of B‐cell‐targeting therapies, may shed new light on the pathogenesis of SSc.

Pathogenic roles of B lymphocytes in systemic sclerosis.

Regulatory T cell-based therapies for autoimmunity.

The current understanding of Treg cell function and the therapeutic potential of enhancing Treg cells in patients with inflammatory disorders are examined.



A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice.

It is demonstrated, by comparing B cell-deficient and control mice, that the expansion of activated and memory T cells in the MRL-lpr/lpr mouse is indeed highly dependent on B cells, suggesting a novel role for B cells in autoimmune disregulation.

B cell depletion therapy in systemic lupus erythematosus

Rituximab is a chimeric mouse-human monoclonal antibody against the B cell-specific antigen CD20, which selectively and profoundly depletes B lymphocytes and has been widely used to treat B cell lymphomas.

B cells: a fundamental role in the pathogenesis of rheumatoid arthritis?

It is evident that B cells play a central role in the pathophysiology of RA and therefore merit further investigation as a therapeutic target.

B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice.

There is strong evidence that B cells are required as APCs to generate pathogenic autoimmune T cell responses and provide a direct correlation between the protection from autoimmune diabetes previously reported in B cell-deficient NOD mice and the lack of anti-GAD65 and anti-heat shock protein 60 Tcell responses in these mice.

The CD19-CD21 signal transduction complex of B lymphocytes regulates the balance between health and autoimmune disease: systemic sclerosis as a model system.

Chronic B cell activation resulting from augmented CD19 expression or signaling through the CD19 pathway may reveal a prototype autoimmune disease susceptibility pathway in mice and humans.

B cells regulate autoimmunity by provision of IL-10

Data show that B cell–derived IL-10 plays a key role in controlling autoimmunity and that recovery was dependent on the presence of autoantigen-reactive B cells.

Quantitative Genetic Variation in CD19 Expression Correlates with Autoimmunity1

Results suggest that modest changes in the expression or function of regulatory molecules such as CD19 may shift the balance between tolerance and immunity to autoimmunity, and autoimmune disease may result from a collection of subtle multigenic alterations that could include incremental density changes in cell surface signaling molecules.

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.

OBJECTIVE Autoantibody production in patients with systemic lupus erythematosus (SLE) is associated with abnormalities of B cell function and phenotype, and clinical responses to B cell depletion therapy (BCDT), based on rituximab, are encouraging, suggests that B cell clones committed to producing antinucleosome and anti-dsDNA antibodies have a relatively rapid turnover compared with B cell clone producing other antibodies.

Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice.

It is demonstrated that B cell depletion in mice can prevent or delay diabetes, reverse diabetes after frank hyperglycemia, and lead to the development of cells that suppress disease.